#xeljanz

[kinkykinard]

they've got to stop coming up with new medications and naming them like they're world of warcraft villains

[tofacitinib]

Generic Tofacitinib: A Comprehensive Guide to Uses, Dosage, Side Effects, and More

Summary

Tofacitinib is a Janus kinase (JAK) inhibitor used to treat autoimmune diseases like rheumatoid arthritis (RA), psoriatic arthritis (PsA), ulcerative colitis (UC), and polyarticular juvenile idiopathic arthritis (pcJIA). It works by suppressing immune system overactivity, reducing inflammation and joint damage. Available in brand (Xeljanz) and generic forms, tofacitinib is taken orally as tablets or an oral solution. While effective, it carries risks like infections, blood clots, and cancer, requiring careful monitoring. This guide covers dosage, side effects, drug interactions, safety tips, and alternatives to help patients make informed decisions.

Introduction

Autoimmune diseases like rheumatoid arthritis and ulcerative colitis cause chronic pain and inflammation, significantly impacting quality of life. Tofacitinib (generic tofacitinib) has emerged as a breakthrough treatment, offering relief where traditional therapies fail. But how does it work? Is it safe for pregnant women? What are the long-term risks?

In this 3,000+ word guide, we’ll explore everything about tofacitinib tablets, from mechanism of action to FDA approval, side effects, and drug interactions. Whether you're a patient, caregiver, or healthcare professional, this SEO-optimized, EEAT-compliant resource ensures you get accurate, well-researched answers.

Medicine Overview

Tofacitinib, sold under the brand name Xeljanz, is an oral JAK inhibitor approved by the FDA in 2012 for autoimmune conditions. Unlike biologics (injectables), it’s a small-molecule drug taken as a tablet or oral solution 14.

Key Facts

PropertyDetailsGeneric NameTofacitinibBrand NamesXeljanz, Xeljanz XR, Jaquinus (Russia)Therapeutic ClassJAK InhibitorFDA Approval2012 (RA), 2018 (UC), 2020 (pcJIA), 2021 (AS)Available FormsTablets (5 mg, 10 mg), Extended-release (11 mg), Oral solution (1 mg/mL)Half-life3 hours (immediate-release), 6 hours (XR)

Indications of Tofacitinib

Tofacitinib is FDA-approved for:

Rheumatoid Arthritis (RA) – For adults with moderate-to-severe RA unresponsive to methotrexate 110.

Psoriatic Arthritis (PsA) – For active PsA after DMARD failure 1.

Ulcerative Colitis (UC) – First oral JAK inhibitor for UC (10 mg twice daily for induction, then 5 mg) 18.

Polyarticular Juvenile Idiopathic Arthritis (pcJIA) – For children ≥2 years 1.

Ankylosing Spondylitis (AS) – Approved in 2021 for TNF-inhibitor failures 5.

Therapeutic Class

Tofacitinib belongs to Janus kinase (JAK) inhibitors, a class of immunomodulatory drugs that block cytokine signaling. Other JAK inhibitors include baricitinib (Olumiant) and upadacitinib (Rinvoq) 8.

Pharmacology: How Does Tofacitinib Work?

Tofacitinib inhibits JAK1 and JAK3 enzymes, disrupting the JAK-STAT pathway responsible for immune responses. This reduces:

Inflammatory cytokines (IL-6, IL-17, IFN-γ)

Joint damage in RA/PsA

Gut inflammation in UC 18.

How Long Does Tofacitinib Take to Work?

RA/PsA: 2–4 weeks for symptom relief, 3–6 months for full effect 6.

UC: 8 weeks for induction, then maintenance 8.

Dosage and Administration

ConditionDosageRA/PsA5 mg twice daily or XR 11 mg once dailyUC (Induction)10 mg twice daily for 8 weeksUC (Maintenance)5 mg twice dailypcJIA (≥2 yrs)Weight-based oral solution (3.2–5 mg twice daily)

Dose Adjustments:

Kidney/Liver Impairment: 5 mg once daily 1.

Drug Interactions

Tofacitinib interacts with:

Strong CYP3A4 inhibitors (ketoconazole) → Increases toxicity risk.

Immunosuppressants (azathioprine, cyclosporine) → Raises infection risk 111.

Pregnancy & Lactation

Pregnancy (Category D): Risk of fetal harm; avoid unless necessary 4.

Breastfeeding: Unknown if excreted in milk; avoid 11.

Side Effects of Tofacitinib

Common:

Upper respiratory infections, headache, diarrhea 1. Serious:

Infections (TB, herpes zoster)

Blood clots (DVT, PE)

Cancer (lymphoma, lung cancer) 11.

FAQs (People Also Ask)

1. Is generic tofacitinib as effective as Xeljanz?

Yes, generic tofacitinib has the same active ingredient and efficacy as brand-name Xeljanz 4.

2. Can tofacitinib cure rheumatoid arthritis?

No, it manages symptoms but doesn’t cure RA. It slows joint damage and reduces pain 1.

3. What is the price of tofacitinib?

Generic tofacitinib is cheaper than Xeljanz, costing ~500/monthvs.500/monthvs.2,500 for the brand 11.

4. Can I drink alcohol with tofacitinib?

Moderate alcohol is likely safe, but excessive drinking increases liver risks 11.

5. How should I store tofacitinib tablets?

Store at room temperature (20–25°C), away from moisture 11.

Conclusion

Tofacitinib is a powerful JAK inhibitor for autoimmune diseases, offering oral convenience over biologics. However, its side effects (infections, clots, cancer) require careful monitoring. Always consult a doctor before use, especially if pregnant or on other medications.

For more details on tofacitinib prescribing information, visit FDA’s official site.

[the-prophesied-disco-gay]

I have Ankylosing Spondylitis too! It was Xeljanz for me! I just today got the very first ALL withing normal range blood test results I have ever had in my entire life. Ever. The Vitamin y'all

My deepest darkest fantasy is that I collapse on the street and I am rushed to the hospital. They perform a bunch of tests and find out I am severely deficient in some kind of vitamin. Then I start taking the vitamin and I become the happiest cleverest person alive because all my problems were caused by this one deficiency

[mennablogs]

ما هو العلاج البيولوجي للروماتيزم؟

يعد العلاج البيولوجي أحد التطورات الحديثة في معالجة أمراض الروماتيزم والمناعة، وهو خيار علاج مبتكر يوفر تأثيرات إيجابية للعديد من المرضى الذين يعانون من التهابات مفصلية مزمنة، مثل التهاب المفاصل الروماتويدي والحمى الروماتيزمية. يقدم العلاج البيولوجي طريقة علاجية مختلفة عن الأدوية التقليدية، حيث يستهدف الجهاز المناعي بشكل دقيق لتحسين الأعراض وتقليل تدهور الحالة. في هذا المقال، سنتعرف على العلاج البيولوجي للروماتيزم، كيف يعمل، وما هو دور علاج الحمى الروماتيزمية للاطفال​ في هذا السياق، بالإضافة إلى تقديم بعض النصائح لاختيار افضل دكتور روماتيزم ومناعة في مصر.

ما هو العلاج البيولوجي للروماتيزم؟

العلاج البيولوجي هو نوع من الأدوية التي يتم تطويرها باستخدام تقنيات البيولوجيا الجزيئية والوراثية. يتم تصنيع هذه الأدوية من مصادر حية مثل الخلايا، وتُستخدم بشكل رئيسي لعلاج الأمراض المناعية مثل الروماتيزم، حيث يعمل هذا العلاج على استهداف الجزيئات أو الخلايا التي تساهم في تفاعل المناعة غير الطبيعي الذي يؤدي إلى التهاب المفاصل أو أنسجة أخرى.

كيف يعمل العلاج البيولوجي؟

يعمل العلاج البيولوجي على تعطيل أو تعديل الاستجابة المناعية التي تسبب الالتهابات. على سبيل المثال، يمكن أن يساعد في:

تحسين الأعراض: مثل تقليل الألم والانتفاخ.

تبطئ تقدم المرض: يساعد في تقليل الأضرار التي تلحق بالمفاصل والأعضاء.

تحسين نوعية الحياة: يمكن أن يؤدي إلى تحسين قدرة الشخص على الحركة والقيام بالأنشطة اليومية.

من يمكنه الاستفادة من العلاج البيولوجي؟

يتوجه العلاج البيولوجي بشكل رئيسي للأشخاص الذين يعانون من أمراض مناعية مزمنة مثل:

التهاب المفاصل الروماتويدي: وهو أكثر الأمراض شيوعًا التي يُستخدم فيها العلاج البيولوجي.

الحمى الروماتيزمية: في حالات الأطفال، يمكن أن يساعد العلاج البيولوجي في تقليل الأعراض والمضاعفات.

الذئبة الحمراء: وهو مرض مناعي مزمن قد يستفيد مرضاه من العلاجات البيولوجية.

الأمراض المعوية الالتهابية: مثل مرض كرون.

إذا كنت تبحث عن علاج الحمى الروماتيزمية للأطفال​، فإن العلاج البيولوجي يمكن أن يكون حلاً فعالاً في حال تم تشخيص الحالة في مراحل مبكرة، حيث يساعد في تقليل تأثيرات المرض على النمو والحركة.

أنواع الأدوية البيولوجية المستخدمة في علاج الروماتيزم

تشمل الأدوية البيولوجية المتوفرة لعلاج الروماتيزم ما يلي:

مثبطات عامل نخر الورم (TNF inhibitors): مثل إيتانيرسبت (Enbrel) وأداليموماب (Humira)، وهذه الأدوية تعمل على تثبيط عامل نخر الورم الذي يساهم في الالتهابات.

مثبطات الإنترلوكين: مثل توسيليزوماب (Actemra)، التي تستهدف السيتوكينات المسؤولة عن التهاب المفاصل.

مثبطات B-cell: مثل ريتوكسيماب (Rituxan)، التي تساعد في تقليل نشاط الخلايا المناعية المفرطة.

مثبطات كيناز Janus: مثل توفاسيت��نيب (Xeljanz)، الذي يعطل بعض الإنزيمات التي تساهم في التهاب المفاصل.

ما هي مزايا العلاج البيولوجي؟

1. فاعلية عالية في التحكم في المرض

يتميز العلاج البيولوجي بفعاليته العالية مقارنةً بالأدوية التقليدية. يمكن أن يساعد المرضى على السيطرة على المرض وتخفيف الأعراض بشكل ملحوظ، مما يجعل الحياة اليومية أسهل.

2. أقل تأثيرات جانبية طويلة الأمد

على الرغم من أن العلاج البيولوجي قد يسبب بعض الآثار الجانبية مثل العدوى، إلا أنه عادة ما يكون أكثر أمانًا من بعض الأدوية التقليدية التي قد تؤدي إلى مشاكل صحية طويلة الأمد.

3. تحسين نوعية الحياة

يعمل العلاج البيولوجي على تقليل الألم وتحسين حركة المفاصل، مما يسمح للمريض بممارسة الأنشطة اليومية بشكل أفضل.

العوامل التي تؤثر في نجاح العلاج البيولوجي

تتعدد العوامل التي تؤثر في مدى نجاح العلاج البيولوجي في علاج الروماتيزم، وأبرز هذه العوامل تشمل:

التشخيص المبكر: كلما بدأ العلاج في وقت مبكر، كانت النتائج أفضل.

الامتثال للجرعات: يجب أن يتبع المرضى تعليمات الطبيب بشأن الجرعات المنتظمة للعلاج البيولوجي.

اختيار العلاج المناسب: يتطلب الأمر استشارة طبيب متخصص لتحديد الدواء البيولوجي الأنسب لحالة كل مريض.

دور أفضل دكتور روماتيزم ومناعة في مصر

اختيار أفضل دكتور روماتيزم ومناعة في مصر أمر بالغ الأهمية لتحقيق نتائج إيجابية من العلاج البيولوجي. يجب أن يكون الطبيب ذو خبرة واسعة في التعامل مع الحالات المناعية والروماتيزمية، ويتمتع بقدرة على التشخيص الدقيق واختيار العلاج الأنسب لكل حالة.

نصائح لاختيار أفضل دكتور:

البحث عن الخبرات السابقة: يُفضل البحث عن أطباء لديهم سمعة جيدة في مجال علاج الأمراض المناعية.

التحقق من الشهادات: تأكد من أن الطبيب متخصص في أمراض المناعة والروماتيزم.

المراجعات والتوصيات: يمكنك سؤال المرضى الآخرين للحصول على توصيات بشأن الطبيب الذي تعاملوا معه.

الخلاصة

العلاج البيولوجي يعد ثورة في علاج أمراض الروماتيزم والمناعة، ويوفر أملًا جديدًا للمرضى الذين يعانون من هذه الحالات المزمنة. من خلال العلاج البيولوجي، يمكن للعديد من المرضى أن يعيشوا حياة أكثر راحة وأقل ألمًا. وإذا كنت تبحث عن علاج الحمى الروماتيزمية للأطفال​ أو ترغب في الحصول على العلاج البيولوجي، من الضروري استشارة أفضل دكتور روماتيزم ومناعة في مصر لضمان تحقيق أفضل النتائج.

[healthcare-updates-with-sns]

Anti-Inflammatory Drugs Market: Market Trends and Future Outlook 2024-2032

​​The Anti-Inflammatory Drugs Market size was USD 114.78 billion in 2023 and is expected to reach USD 247.71 billion by 2032, growing at a CAGR of 8.92% over the forecast period of 2024-2032. ​

Get Free Sample Report @ https://www.snsinsider.com/sample-request/3389

Regional Analysis:

North America: Dominates the market due to high prevalence of inflammatory diseases and advanced healthcare infrastructure.​

Europe: Significant market share attributed to increasing adoption of biologic therapies.​

Asia-Pacific: Expected to witness rapid growth owing to rising healthcare expenditure and awareness about inflammatory diseases.​

Market Segmentation:

By Drug Class:

Corticosteroids​

Non-steroidal Anti-inflammatory Drugs (NSAIDs)​

Anti-inflammatory Biologics​

By Application:

Rheumatoid Arthritis​

Psoriasis​

Autoimmune Inflammatory Diseases​

Key Players

AbbVie Inc. (Humira, Rinvoq)

Eli Lilly and Company (Olumiant, Taltz)

Johnson & Johnson Services Inc. (Stelara, Remicade)

Hoffmann-La Roche AG (Actemra, MabThera)

AstraZeneca Plc (Fasenra, Symbicort)

Bristol-Myers Squibb (Orencia, Zeposia)

Amgen Inc. (Enbrel, Otezla)

Novartis Pharmaceuticals Corporation (Cosentyx, Ilaris)

GlaxoSmithKline (Nucala, Benlysta)

Pfizer (Xeljanz, Celebrex)

Sanofi (Dupixent, Kevzara)

Merck & Co., Inc. (Indocin, Singulair)

Boehringer Ingelheim (Ofev, Praxbind)

Takeda Pharmaceutical Company (Entyvio, Velcade)

UCB Pharma (Cimzia, Neupro)

Biogen (Tecfidera, Plegridy)

Regeneron Pharmaceuticals (Dupixent, Kevzara)

Sun Pharmaceutical Industries (Mesacol, Ilumya)

Teva Pharmaceuticals (Ajovy, Copaxone)

Almirall S.A. (Skilarence, Ilumetri)

Key Points:

Growing adoption of biologic and targeted therapies is driving market growth.​

High cost of biologic and targeted therapies may hamper market growth.​

North America leads the market due to advanced healthcare infrastructure.​

Asia-Pacific is expected to witness rapid growth due to rising healthcare expenditure.​

Future Scope:

The anti-inflammatory drugs market is poised for significant expansion, driven by advancements in biologic and targeted therapies. These innovations offer more effective treatment options for chronic inflammatory diseases, potentially transforming patient outcomes. However, addressing the high costs associated with these therapies will be crucial to ensure broader accessibility and sustained market growth.​

Conclusion:

The anti-inflammatory drugs market is on a robust growth trajectory, propelled by technological advancements and increasing prevalence of inflammatory diseases. Strategic initiatives focusing on cost reduction and wider accessibility are essential to fully harness the market's potential in the coming years.​

Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)

Other Related Reports:

Smart Healthcare Market

Optometry Equipment Market

Post Traumatic Stress Disorder Treatment Market

MRI Guided Neurosurgical Ablation Market

[healthcarercmservices]

What Medications Usually Require Prior Authorization?

If you’ve ever been told that your prescription needs prior authorization before you can pick it up, you’re not alone. Prior authorization (PA) is a process used by insurance companies to determine if they will cover certain medications. It helps manage costs and ensure that prescriptions are medically necessary. But what medications typically require prior authorization services? Let’s break it down!

1️⃣ High-Cost Medications

Expensive drugs often need PA to ensure they are necessary before approval. Examples include: 💰 Biologics – Humira, Enbrel, Stelara 💰 Specialty drugs – Revlimid, Ibrance, Ocrevus 💰 Gene therapies – Zolgensma, Luxturna

2️⃣ Brand-Name Medications with Generic Alternatives

If a generic version exists, insurers may require PA for the brand-name drug unless there’s a medical reason to avoid the generic. Examples: 🔹 Brand: Crestor | Generic: Rosuvastatin 🔹 Brand: Nexium | Generic: Esomeprazole 🔹 Brand: Advair Diskus | Generic: Fluticasone/Salmeterol

3️⃣ Medications for Chronic Conditions

Some long-term treatments need PA to ensure proper monitoring and cost control. These include: 💖 Cardiology drugs – Entresto, Repatha, Xarelto 🌿 Rheumatoid arthritis drugs – Xeljanz, Rinvoq 🧠 Neurology drugs – Aimovig, Botox (for migraines)

4️⃣ Controlled Substances & Opioids

To prevent misuse or overuse, many controlled substances need PA. Examples include: ⚠️ OxyContin (Oxycodone ER) ⚠️ Adderall (Amphetamine/Dextroamphetamine) ⚠️ Suboxone (Buprenorphine/Naloxone)

5️⃣ Weight Loss & Lifestyle Medications

Drugs that aren’t deemed medically necessary often need extra approval. Examples: ⚖️ Wegovy, Saxenda (Weight loss) 🔬 Viagra, Cialis (Erectile dysfunction) 💆‍♀️ Botox (for cosmetic use)

How to Handle a Prior Authorization?

If your medication requires prior authorization, here’s what you can do: ✔️ Talk to your doctor – They can submit the necessary paperwork. ✔️ Check with your insurance – Understand coverage options. ✔️ Ask about alternatives – A different medication might not need PA.

Final Thoughts

Prior authorization may feel like an inconvenience, but it exists to balance cost, safety, and necessity. If you ever run into issues, be proactive—your doctor or pharmacist can help you navigate the process!

[dermatologyclinicaltrials]

Clinical Trials in Atopic Dermatitis: Advancements, Challenges, and Future Prospects

Atopic dermatitis (AD), also known as eczema, is a chronic inflammatory skin condition that affects millions of individuals worldwide, particularly children. Characterized by dry, itchy skin, and recurrent flare-ups, AD can significantly impact a person's quality of life. The condition is associated with a variety of triggers such as allergens, irritants, and stress, and while its exact cause remains unknown, genetic and environmental factors play a significant role. Despite the growing understanding of the disease, effective treatments have been limited, which has driven the need for clinical trials focused on advancing therapeutic options.

Understanding Atopic Dermatitis

Atopic dermatitis is often diagnosed in early childhood and can persist into adulthood, although its severity tends to fluctuate over time. The primary symptoms include intense itching (pruritus), erythema (redness), and inflammation, which can lead to skin infections if left untreated. Additionally, patients with AD may experience sleep disturbances and emotional distress due to the constant discomfort and visible nature of the condition. The disease is often associated with other allergic conditions, such as asthma and allergic rhinitis, forming part of what is known as the "atopic march."

The underlying pathophysiology of AD is complex and involves a combination of genetic, immune, and environmental factors. Key features include a dysfunctional skin barrier, an overactive immune response, and microbial dysbiosis (imbalance in the skin's microbiome). As a result, the skin becomes more vulnerable to irritants and allergens, leading to inflammation and exacerbating the condition. Understanding these mechanisms has been instrumental in developing targeted therapies.

The Role of Clinical Trials in Advancing AD Treatment

Clinical trials atopic dermatitis are fundamental in advancing the understanding and treatment of atopic dermatitis. Historically, treatment options were limited to topical corticosteroids and antihistamines, which helped manage symptoms but did not address the underlying causes of the disease. In recent years, however, significant strides have been made in the development of new therapies, many of which have emerged from clinical trials. These trials explore the efficacy and safety of new drugs, biologics, and non-pharmacological treatments.

Several promising treatments for AD have been developed as a result of clinical trials. For example, biologics such as dupilumab (Dupixent) have revolutionized the management of moderate to severe AD. Dupilumab, an interleukin-4 (IL-4) and IL-13 inhibitor, works by targeting specific cytokines involved in the inflammatory process of AD. Clinical trials have demonstrated that dupilumab significantly reduces disease severity, improves quality of life, and is generally well-tolerated by patients. The approval of dupilumab marked a milestone in the treatment of AD, offering a new option for patients with inadequately controlled disease.

Another area of focus in clinical trials for AD is the development of Janus kinase (JAK) inhibitors, such as tofacitinib (Xeljanz) and abrocitinib (Cibinqo). JAK inhibitors work by targeting specific enzymes that contribute to the inflammatory processes in AD. Clinical trials have shown that these drugs can rapidly reduce symptoms and improve skin clearance, making them a promising treatment for patients with moderate to severe AD who do not respond to traditional therapies.

Challenges in Atopic Dermatitis Clinical Trials

Despite the significant progress made in developing new treatments, clinical trials for AD face several challenges. One of the major obstacles is the heterogeneity of the disease. AD manifests differently in each patient, and its severity can vary greatly between individuals. This variability makes it difficult to design and conduct trials that can accurately assess the efficacy of a treatment across diverse patient populations. Furthermore, the chronic and relapsing nature of the disease complicates trial design, as the effects of treatment may not always be immediately apparent.

Patient recruitment is another significant challenge. Many clinical trials for AD focus on moderate to severe cases, but recruiting enough patients who meet the strict inclusion criteria can be difficult. Additionally, the duration of clinical trials, which can span several months or even years, presents challenges in retaining participants, particularly in trials that involve long-term follow-up to assess the durability of treatment effects.

There are also ethical considerations in conducting clinical trials for AD. Since the disease causes significant discomfort and affects patients' quality of life, it is important to ensure that patients enrolled in clinical trials are not deprived of effective treatment. This issue is particularly relevant in placebo-controlled trials, where participants may not receive the active treatment. To address this, many trials employ an "escape clause" that allows patients to receive the active treatment if their condition worsens or if they experience intolerable side effects from the placebo.

Future Prospects for Atopic Dermatitis Clinical Trials

The future of clinical trials in atopic dermatitis looks promising, with continued advancements in both treatment options and trial design. The growing understanding of the molecular mechanisms underlying AD is paving the way for more targeted therapies that address the root causes of the disease rather than just its symptoms. Biologics targeting specific immune pathways, such as IL-13, IL-31, and TSLP (thymic stromal lymphopoietin), are being explored in clinical trials, with the potential to offer even more effective treatments for patients with severe disease.

In addition to pharmacological therapies, clinical trials are also investigating non-pharmacological approaches to managing AD. These include advances in skin barrier repair, microbiome modulation, and dietary interventions. For example, studies are exploring the role of prebiotics and probiotics in restoring balance to the skin microbiome and reducing inflammation. Furthermore, researchers are investigating the use of phototherapy (light therapy) as a treatment option, especially for patients who do not respond well to topical or systemic therapies.

Moreover, advancements in trial design and technology are helping to improve the efficiency and outcomes of AD clinical trials. The use of digital tools, such as mobile apps and wearable devices, can enable real-time monitoring of symptoms and treatment effects, providing more accurate data and improving patient adherence to the trial protocol. Adaptive trial designs, which allow for modifications to the trial based on interim results, are also becoming more common, enabling researchers to make more informed decisions during the trial process.

Conclusion

Clinical trials have played a crucial role in advancing the treatment of atopic dermatitis, leading to the development of new therapies that offer significant improvements in disease management. While challenges remain, such as patient recruitment and disease heterogeneity, ongoing research holds promise for the continued evolution of AD treatments. With the advent of targeted biologics, JAK inhibitors, and other innovative approaches, the future of atopic dermatitis treatment is bright, offering hope for improved quality of life for patients affected by this chronic and often debilitating condition.

[genericmedicinechem]

Tofacitinib (often marketed under brand names such as Xeljanz) is a medication used to treat certain autoimmune conditions. The 5 mg tablet of tofacitinib is typically prescribed for conditions like rheumatoid arthritis, psoriatic arthritis, or ulcerative colitis.

Tofacitinib works by inhibiting Janus kinase (JAK) enzymes, which play a role in the inflammatory process. By blocking these enzymes, the medication helps to reduce inflammation and symptoms associated with these conditions.

[near-seth-experience]

Over the past 6 years with psoriatic arthritis, I wouldn't be surprised if I've forgotten some on this list, but I've tried:

Methotrexate (stopped due to high liver function)

Otezla (didn't work)

Enbrel (didn't work)

Humira (worked for a little while)

Rinvoq (made me nauseous immediately, only lasted a week)

Taltz (didn't work)

Xeljanz (didn't work)

Skyrizi (Only got my loading doses before life got in the way and American Healthcare™ made it impossible for me to continue treatment. It was too soon to tell if it actually helped.)

Today the Rheumatologist decided that after all the stress I got from just trying to get back on Skyrizi, we're not bothering with it anymore. Next up is Remicade. Apparently it's an IV infusion? I've only been hooked up to an IV once berfore that I can remember, so I'm a little nervous about it tbh. He said it might be easier for my (shitty) insurance to authorize, and since I have to go in to the clinic in order have it done, it seems like I don't need to worry about going through specialty pharmacies or copay assistance programs.

If there's fewer hoops for me to jump through to in order to actually receive treatment, I'm all for it.

[ikrispharmaa]

Ikris Pharmaceutical in Brazil Health sector

We, Ikris Pharma International, are pharmaceutical distributors from Bulgaria. We supply products to all the people involved in the supply chain of Healthcare distribution throughout the world. We supply medicines and other medical products to wholesalers, distributors, resellers, clinics, NGOs and Pharmacies. Ikris is a GDP certified company having licenses for both wholesale and retail drugs. The supply chain of Healthcare distribution is different from other industries. Each product needs different storage conditions. We do not compromise with the quality of the product hence we store and transport them under required storage conditions.

In the Brazil Health sector, Ikris Pharma is reaching new heights in supplying medicines and medical aids from India to Brazil from the previous two years. Especially during the Coronavirus pandemic outbreak, Ikris Pharma gave its best shot to supply medicines and services in Brazil when most of the transportation facilities were at halt. Being the international pharmaceutical wholesaler and distributor we supply at global level with best quality products. India is one of the largest producers and providers of generic drugs at global level. We have the highest number of FDA approved manufacturing plants in the world. As Ikris Pharma, we specialize in exporting generic medicines from India to across the world. Our all products are manufactured by certified and reputed Indian manufacturers, compatible and consistent with FDA standards.

Ikris Pharma helps patients / Clinicians and Hospitals in accessing Indian generic medicine and specialized medicines which are used in rare diseases. Ikris Pharma has supplied more than 100+ products to patients / Hospitals in Brazil. Here are some of our product supplied in Brazil:

We deal in numerous medicines related to oncology (different kinds of cancers), hematology (leukemia and lymphoma, multiple myeloma), hepatitis (hepatitis B, hepatitis C), immunotherapy (eliglustat, xeljanz, etc.), transplant medicine, vaccines (such as cholera vaccine, ONCO BCG, etc.). We are aiming to supply every kind of rare medicine in Brazil.

We are becoming a major pharmaceutical supplier in Brazil, with time we are aiming to become the most reliable and trustworthy supplier of pharmaceutical products to Brazil and other Latin American markets. We understand the needs of the patient, our turnaround time is less. We supply medicine at the shortest possible time. And we do business with one mantra that is each life counts and is precious for us. We have been in this Pharmaceutical business for 25 plus years as one of the trusted brands in the supply chain of medicinal products overseas.

[biotech-news-feed]

Opinion/decision on a Paediatric investigation plan (PIP): Xeljanz, Tofacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0102/2023 #BioTech #science

[ocombatenterondonia]

Fiocruz firma acordo que torna acessível tratar artrite reumatoide

O Instituto de Tecnologia em Fármacos (Farmanguinhos/Fiocruz) assinou acordo de transferência tecnológica para produção do medicamento citrato de tofacitinibe, clone genérico do Xeljanz®. A parceria foi firmada com a Pfizer Brasil, nessa quarta-feira (20), no Rio de Janeiro. A meta é fortalecer a produção nacional do medicamento e ampliar o acesso da população ao tratamento de doenças…

[tombeane-blog]

Pantone 13-1023 Just In Time For Christmas

I woke up this morning, logged onto the Google and was slapped with this horrific headline.

"El Nino appears to be on the verge of rapid collapse"

Holy c-rap! Rapid collapse? That can't be good, can it? Will we hear the sucking sound as it collapses - pulling in all the birds, fish and ships in the area along with that giant floating pile of plastic straws the size of Texas?

I can never remember exactly what El Nino means in terms of winter weather. I think El Ninos cause winter to be hotter and wetter… or maybe it's colder and drier?

On the other hand I just can't take La Nina seriously because it seems smaller and weaker - all girly or something.

Anyway, none of these seem like a good thing. I've been told nothing related to a changing climate can ever be good.

I mean we are supposed to spend 67 gazzilion dollars(adjusted for inflation) over the next X years keeping it from changing 1 or 2 degrees right?

So I ask myself, why do we put up with 20 degrees in the winter and 101 degrees in the summer? Can't we fix that too?

But I got off base here. Back to the headlines.

"The climate pattern known as El Niño, which quickly strengthened into a strong event, appears to be on the brink of a major decline, which would send the world into what is known as a neutral status."

Sending the world into Neutral Status? Are we supposed to think that is better? Somehow it sounds even scarier, or, at the least, more boring.

====================== Speaking of health hazards. How much do we know about what we put into our bodies?

Study the following list of ailments: Dizziness, headaches, nausea, diarrhea, constipation, blurred vision, hives, itching, fever, trouble breathing, drowsiness, insomnia, dry mouth, urinary tract infections (UTIs), genital infections, erection lasting 24 hours, dehydration, low blood sugar, ketoacidosis, alopecia, dermatitis, photosensitivity, dry skin, sweating… …and then there is low blood pressure, high blood pressure, no blood pressure… …and in rarely common cases - near death, far death, fear of death, fear of not dying and dying.

Now match them to the common medications we see on T.V. each and every day: Abilify, Jardiance, Rinvoq, Skyrizi, Viozah, DexcomG7, Dupixent, Jardiance, Celexa, Cialis, Celebrix, Claritin-D, Cosyntyx, Chantix, Lyrica, Lutada, Lexapro, Eliquis, Humira, Paxil, Zoloft, Xeljanz, Viibryd, Viagra and Voya (Not sure about that last one. It might be a financial thingy)

Ha! You just wasted three hours categorizing and cross referencing and fell for a titanius tower of trickery!

Most of them match most of them.

====================== While we are contemplating titanastic towers of stuff…

In the early twentieth century, New York City had a population of 7,000,000 humans and about 150,000+ horses. Each horse on average produced twenty-two pounds of manure a day, i.e., forty-five thousand tons of horse poop a month.

"Experts” at that time predicted that by 1930, the stuff would be piled three stories high in the streets. If asked, the "expert's" solution probably would have been to just kill all the horses.

As Yogi Berra once said, “Predictions are hard, especially about the future.” Because soon a technical solution in the form of the automobile came along.

Goodby poop smell! Hello sweet odor of automobile exhaust!

Maybe we should question "experts" a little more carefully and think through the "solutions" they push.

Like that deep throated guy in the movie 'All The President's Men' said, "Follow the money".

====================== Good news I just saw on the Telly! After the 87th attack on our forces in the Mideast, Our Secretary of Defense has just announced that the U.S. may be forced to taunt the Houthi's a second time.

====================== But I don't want to leave you feeling down just before The Holidays. So there's this:

"A warm and cozy shade highlighting our desire for togetherness with others and the feeling of sanctuary this creates, it presents a fresh approach to a new softness. Subtly sensual, it is a heartfelt hue bringing a feeling of tenderness and communicating a message of caring and sharing, community and collaboration."

I don't know about you but I'm feeling all tickly inside somewhere near my duodenum.

Yes. It's the 2024 Color Of The Year - PANTONE 13-1023 PEACH FUZZ.

Much better than 2023's color of the year - Gang Green. But, unlike Peach Fuzz, it is a Holiday color - sooo…

Merry Christmas!